ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Tyrosine kinase inhibitors (TKIs) targeting BCR‐ABL for CML therapy have effectively improved the survival of CML patients; however, about 20% of CML patients have not been benefited from TKIs treatment, commonly due to TKIs resistance which lead to disease relapse and progression.46, 47, 48